Abicipar Pegol
drugOn this page
Also known as Agn-150998MP-0112MP-0260Mp0112P7FHD7AG35Vegf-a binding darpin
Summary
Abicipar Pegol (CHEMBL4297684) is a phase-3 clinical-stage protein (ATC S01LA07); indicated across 5 conditions including age-related macular degeneration and macular degeneration.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Protein
- ATC class: S01LA07
- Indications: 5 conditions
- Clinical trials: 11
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4297684 |
| Name | Abicipar Pegol |
| Type | Protein |
| Max phase | 3 |
| ATC | S01LA07 |
Also known as: Abicipar pegol, Agn-150998, AGN-150998, MP-0112, MP-0260, Mp0112, MP0112, P7FHD7AG35, Vegf-a binding darpin, ABICIPAR PEGOL
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| age-related macular degeneration | 3 | MONDO:0005150 | EFO:0001365 |
| macular degeneration | 3 | MONDO:0003004 | EFO:0009606 |
| ocular vascular disorder | 3 | MONDO:0005552 | EFO:0005753 |
| wet macular degeneration | 1 | MONDO:0005417 | EFO:0004683 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 11.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 5 |
| PHASE1 | 4 |
| PHASE3 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02462486 | PHASE3 | COMPLETED | Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration |
| NCT02462928 | PHASE3 | COMPLETED | A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration |
| NCT01397409 | PHASE2 | COMPLETED | Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD) |
| NCT02181504 | PHASE2 | COMPLETED | A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration |
| NCT02181517 | PHASE2 | COMPLETED | A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration |
| NCT02186119 | PHASE2 | COMPLETED | A Study of Abicipar Pegol in Patients With Diabetic Macular Edema |
| NCT03539549 | PHASE2 | COMPLETED | A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participants With Neovascular Age-related Macular Degeneration (AMD) |
| NCT01042678 | PHASE1 | TERMINATED | Study of MP0112 Intravitreal Injection in Patients With Diabetic Macular Edema |
| NCT01086761 | PHASE1 | TERMINATED | Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration |
| NCT02859766 | PHASE1 | COMPLETED | Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Patients With Neovascular AMD |
| NCT03335852 | PHASE1 | COMPLETED | Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AMD |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).